Related Experiment Videos
Felty's syndrome.
Geza P Balint1, Peter V Balint
1Fourth General Rheumatology Department, National Institute of Rheumatology and Physiotherapy, Budapest, 25-29 Frankel L. St, 1023 Hungary. balintg@mail.datanet.hu
Best Practice & Research. Clinical Rheumatology
|September 30, 2004
Summary
Felty's syndrome (FS) is a rare RA complication with severe joint issues and infections due to neutropenia. Treatments like DMARDs and G-CSF show promise, with splenectomy offering immediate neutropenia relief.
Area of Science:
- Rheumatology
- Immunology
- Hematology
Background:
- Felty's syndrome (FS) is a rare triad of rheumatoid arthritis (RA), neutropenia, and splenomegaly, affecting <1% of RA patients.
- FS presents with severe joint destruction, significant extra-articular manifestations, and recurrent bacterial infections due to neutropenia.
- Neutropenia in FS results from decreased granulopoiesis and increased peripheral granulocyte destruction, contributing to increased mortality.
Purpose of the Study:
- To summarize the clinical characteristics, pathogenesis, and treatment options for Felty's syndrome.
- To highlight the diagnostic markers and immunogenetic associations in FS patients.
- To review the efficacy of current and emerging therapies for FS.
Main Methods:
- Literature review of Felty's syndrome focusing on clinical presentation, etiology, and management.
- Analysis of diagnostic criteria including rheumatoid factor (RF), antinuclear antibody (ANA), and HLA-DR4*0401 antigen.
- Evaluation of treatment outcomes for disease-modifying anti-rheumatic drugs (DMARDs), granulocyte colony-stimulating factor (G-CSF), and splenectomy.
Main Results:
- FS patients exhibit severe joint damage, extra-articular symptoms (nodules, vasculitis, ulcers), and high rates of RF and ANA positivity.
- Neutropenia in FS is linked to decreased granulopoiesis and increased granulocyte destruction, with some patients showing large granular lymphocyte (LGL) expansion.
- Methotrexate (MTX) is an effective DMARD for FS neutropenia; G-CSF shows encouraging results, and splenectomy provides rapid neutropenia improvement but less impact on infection rates.
Conclusions:
- Felty's syndrome requires comprehensive management addressing both rheumatologic and hematologic aspects.
- Early diagnosis and appropriate treatment, including DMARDs and potentially G-CSF or splenectomy, are crucial for improving outcomes and reducing mortality.
- Further research into biological agents is warranted for managing this complex RA subset.